Clinical Research Directory

Inclusion Criteria: 1. Inoperable stage IIIB-IV patients with non-small cell lung cancer; 2. BRAF V600E mutation; 3. Dabrafenib and Trametinib are planned for treatment, and the survival period is expected to be more than 3 months; 4. ECOG PS 0/1; 5. The diameter of the primary lesion should be at least 1cm; 6. Previous or current aspirin treatment was allowed Exclusion Criteria: 1. The patient is currently receiving other anticoagulant therapy; 2. The patient was previously treated with systemic anti-NSCLC; 3. The patient had other positive driver mutations, including EGFR, ALK, ROS1, MET14, RET, etc. 4. The patient had contraindications for dalafenib or trametinib and aspirin use; 5. Patients who refused follow-up visits;